The Global Irritable Bowel Syndrome Treatment Market Size accounted for USD 2.1 Billion in 2021 and is projected to achieve a market size of USD 4.7 Billion by 2030 rising at a CAGR of 9.5% from 2022 to 2030. The increasing prevalence of IBS primarily fuels the irritable bowel syndrome (IBS) treatment market share. Additionally, rise in gastrointestinal disorders among population is a popular irritable bowel syndrome treatment market trend that is fueling the industry demand from 2022 to 2030.
Irritable Bowel Syndrome Treatment Market Report Statistics
IBS is a gastrointestinal functional disorder of the intestine that is characterized by contractions of the colon muscle. The big intestine is affected by irritable bowel syndrome. Irritable bowel disorder is linked to bowel malfunction and happens mainly in the elderly. Bowel function and bloating constipation, diarrhea, abdomen, disturbances, and discomfort are some of the prevalent symptoms of irritable bowel syndrome. This syndrome is usually tested in the blood and endoscopies. Bowel syndrome irritation is a prevalent condition and the irritable bowel syndrome is not completely cured.
Global Irritable Bowel Syndrome IBS Treatment Market Dynamics
Irritable Bowel Syndrome Treatment Market Report Coverage
|Irritable Bowel Syndrome Treatment Market
|Irritable Bowel Syndrome Treatment Market Size 2021
|USD 2.1 Billion
|Irritable Bowel Syndrome Treatment Market Forecast 2030
|USD 4.7 Billion
|Irritable Bowel Syndrome Treatment Market CAGR During 2022 - 2030
|Irritable Bowel Syndrome Treatment Market Analysis Period
|2018 - 2030
|Irritable Bowel Syndrome Treatment Market Base Year
|Irritable Bowel Syndrome Treatment Market Forecast Data
|2022 - 2030
|By Type, By Product, And By Geography
|North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|Key Companies Profiled
|Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx.
|Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Irritable Bowel Syndrome Treatment Market Dynamics
The increased incidence of target disease and the increased use of medicines for target disease are driving the industry. Furthermore, increasing marketing of current products in various areas over the forecast period is projected to accelerate development. Linzess ' increased acceptance has made a major contribution to sales development in the United States, Europe, and Japan. In January 2019, Linzess was adopted in China, which will further increase the industry. The industry is mostly under-served and pharmaceutical companies have significant possibilities in this region for addressing several unmet requirements. There are presently a number of promising goods that can further accelerate development under clinical studies. Product sales are expected to increase considerably over the forecast period owing primarily to the growing prevalence of the population and the marketing of new medicines to treat IBS. The irritable gastrointestinal syndrome is one of the most prevalent functional illnesses, and its worldwide incidence is estimated to be 10-15%. It is estimated that IBS is affected by around 25-45 million in the US in 2016 according to the International Foundation for Gastrointestinal Disorders (IFFGD). About 2 out of 3 patients with IBS are women and most of them are under 50 years of age. There is no knowledge of the precise cause of the diseases and symptoms can be a disorder of the interactions between the mind, nervous system, and the intestine. This can lead to ordinary bowel feeling and motion modifications. The IFFGD study showed that around 2000 IBS patients have typically been diagnosed 6.6 years after their symptoms have commenced. Some 20-40% of all gastroenterology patient visits are due to irritable bowel syndrome symptoms. But countless individuals do not know and do not know that their symptoms suggest a disease that is medically recognized. This leads to countless awareness campaigns to increase awareness of the situation.
The IBS Network in the UK, for example. In April 2018, several operations were conducted to solve the disease's stigma. The campaign was designed to assist individuals with IBS and doctors fighting their symptoms. These campaigns and projects are anticipated to increase awareness of the disease and promote therapy for patients. This will accelerate market growth for IBS therapy in turn.
Irritable Bowel Syndrome Treatment Market Segmentation
The worldwide irritable bowel syndrome treatment market is split based on type, product, and geography.
Irritable Bowel Syndrome Treatment Market By Type
According to the irritable bowel syndrome treatment industry analysis, the IBS-D sub-segment dominated with 55% of the share in 2021. Due to the increased incidence and increased use of drugstuffs like Linzess/Constella and Amitiza, IBS-C is expected to gain significant growth rate from 2022 to 2030. In addition, the segment is anticipated to show the fastest growing growth rate of the IBS industry over the prediction era, as promising products such as SYN-010 and Tenapanor, presently undergoing clinical trials, are anticipated to be launched AstraZeneca, Allergan, Ironwood, and Astellas.
Irritable Bowel Syndrome Treatment Market By Product
As per the irritable bowel syndrome treatment market forecast, Linzess/Constella (Linaclotide) was projected to be the biggest product segment generating income in 2021. The high growth in the segment is credited to the variables like increasing acceptance of the product in significant areas such as the U.S., the UK, Germany, Spain, Italy, and Japan. In addition, the growth rate in Japan in 2021 in Linzess was considerable. It is predicted that the Linzess/Constella section will record the highest development in the prediction. Linaclotide in the United States is marketed as Linzess by Ironwood and Allergan and is sold as Constella to Allergan in Europe. The exclusive rights to create and market Linaclotide as linzess are exclusively in Japan and China, Astellas, and AstraZeneca.
Irritable Bowel Syndrome Treatment Market Regional Outlook
The Middle East & Africa (MEA)
Irritable Bowel Syndrome Treatment Market Regional Analysis
North America was the biggest sales region in 2021 and the same trend is anticipated over the forecast period. Due to the absence of important players in the industry, a well-established health care infrastructure, and higher patient awareness, the region was dominant.
The presence of a big target population and the increasing marketing for IBS products in the area is projected to represent Europe as the fastest growing region over the forecast period. In addition, increasing awareness-raising projects in the region can accelerate market growth. Increased awareness of accessible patient therapy is a key driver of the worldwide irritability of bowel syndrome. Increased patients, increased population aging, rising efficiency demands, and an increase in occurrence, prevalence, and awareness of irritable bowel syndrome and worldwide bowel syndrome are anticipated to grow the market.
Irritable Bowel Syndrome Treatment Market Players
Some of the key players in the market are Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx. The main players have adopted distinct approaches to increasing their market shares, such as mergers and acquisitions. A few years back, for example, Bausch Health purchased a portfolio of Salix Pharmaceuticals focusing on gastrointestinal medicine.
In order to expand its market presence, players are also focused on launching their products in distinct areas. Ironwood Pharmaceuticals and AstraZeneca obtained marketing permission for Linzess in China in January 2019, for example, to enhance their market position.
The market size of irritable bowel syndrome treatment market in 2021 was accounted to be USD 2.1 Billion.
The projected CAGR of irritable bowel syndrome treatment market during the analysis period of 2022 to 2030 is 9.5%.
The prominent players of the global irritable bowel syndrome treatment market are Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx.
North America held the dominating irritable bowel syndrome treatment during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for irritable bowel syndrome treatment during the analysis period of 2022 to 2030.
Rising prevalence of IBS, increasing incidences of gastrointestinal disorders, and growing geriatric population drives the growth of global irritable bowel syndrome treatment market.
Based on type, IBS-D segment is expected to hold the maximum share irritable bowel syndrome treatment market.